Physician profile

Romeo Massoud

Surgical Critical Care · Lawrenceville, GA

NPI 1194875237

$26,859.83

in general payments reported to CMS, 2019-2025

41 companies · $15K in 2025

The $15K reported for 2025 was more than what 97% of Surgical Critical Care providers received nationally (typical 2025 total: $234).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$12,850.00
Food and Beverage$3,906.38
Travel and Lodging$968.26
Education$20.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Aroa Biosurgery Incorporated $16,450.89 2022-2025
Intuitive Surgical, INC. $7,158.45 2019-2024
Stryker Corporation $511.36 2022
Integra Lifesciences Corporation $382.66 2021-2025 Integra, Primatrix, Integra Dermal Regeneration Template
Polynovo North America LLC $354.92 2021-2025 Novosorb Btm
Tela Bio, INC. $328.18 2024-2025 Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex)
Kci USA, INC. $155.16 2019-2023 Abthera Advance
Baxter Healthcare $128.89 2021-2025 Perclot, Seprafilm
Ethicon US, LLC $125.21 2020-2025 Enseal
Lexington Medical, INC. $106.81 2022
Alexion Pharmaceuticals, INC. $96.84 2020-2022
Portola Pharmaceuticals, LLC $91.82 2019-2020
Depuy Synthes Sales INC. $86.36 2025 Matrixrib
Prytime Medical Devices, INC. $79.62 2024 Er-Reboa Plus
Z-Medica, LLC $70.71 2019-2020
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $67.85 2023-2024 Andexxa
Access Pro Medical, LLC $66.57 2025 Matriderm
Kerecis Limited $61.41 2023-2024 Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide
Bioventus LLC $52.45 2022-2023
Teleflex LLC $36.10 2019-2022
Takeda Pharmaceuticals U.S.A., INC. $35.53 2022-2025 Gattex
Medline Industries Lp $34.55 2019
Kls-Martin L.P. $30.52 2024
Solventum Corporation $27.47 2025 Prevena, V.A.C. Veraflo Cleanse Choice
Haemonetics Corporation $23.84 2019
Lifenet Health $23.55 2023
Organogenesis INC. $23.20 2021
Biom'Up Sa $23.03 2019
Octapharma USA, INC. $22.94 2025 Fibryga
Biom'Up France Sas $21.92 2020
Boston Scientific Corporation $20.13 2025 Spyglass Discover
Csl Behring $20.00 2024 Kcentra
Avita Medical Americas, LLC $19.74 2025 Cohealyx, Recell, Permeaderm
Acell, INC. $18.65 2019
Innocoll Pharmaceuticals Limited $18.56 2022
Convatec INC. $15.95 2022
Smith+Nephew, INC. $15.42 2025 Grafix Pl, Stravix
Acera Surgical, INC. $15.38 2019
Hydrofera LLC $15.06 2024 Hydrofera Blue
Allergan, INC. $13.13 2019
Reprise Biomedical, INC. $9.00 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Romeo Massoud

$26,859.83

in general payments reported 2019-2025

Years
2019-2025
Top company
Aroa Biosurgery Incorporated
Context
The $15K reported for 2025 was more than what 97% of Surgical Critical Care providers received nationally (typical 2025 total: $234).

https://glasscript.com/doctor/99379/romeo-massoud

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.